Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision label was updated from v3.5.2 to v3.5.3, indicating a minor version change to the site display rather than a change to the clinical trial content.SummaryDifference0.1%

- Check18 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedMedullary thyroid carcinoma is now listed as a condition, and the Genetic and Rare Diseases Information Center has been added to the Resources section.SummaryDifference0.2%

- Check47 days agoChange DetectedRevision updated to v3.5.0, replacing v3.4.3.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.4.3 is shown instead of v3.4.2. There are no visible changes to the study information or user actions on the page.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded Revision: v3.4.2. Removed the funding-status notice and the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.